Semaglutide ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice.

• Tác giả: Cai-Yu Chen, Xue Gong, Li Guo, Pedro A Jose, Xiao-Ping Li, Xuan Liu, Zhi-Zhao Liu, Yang Tang, Chun-Yu Zeng, Li-Ping Zeng, Jian-Li Zhang, Jun-Kai Zhang, Shuo Zheng
• Ngôn ngữ: eng
• Ký hiệu phân loại: 616.716 *Disorders of metabolic origin
• Thông tin xuất bản: United States : Acta pharmacologica Sinica , 2025
• Bộ sưu tập: NCBI
• ID: 494040

Tóm tắt

Pre-pregnancy obesity (PPO) seriously threatens the health of both mother and offspring. Pre-pregnancy weight management is particularly important for the prevention of metabolic diseases in offspring. Semaglutide is one of the most effective glucagon-like peptide-1 agonizts for the management of obesity and metabolic diseases, but little is known about its effect on the long-term health of offspring. In this study we investigated the effects of semaglutide administered before pregnancy on the offspring health from PPO mice. PPO mice model was established by feeding with high-fat diet for 16 weeks, and then injected with semaglutide (30 nmol/kg